Liam Ratcliffe

Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA.

Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT.

Pfizer Ltd. is a biopharmaceutical company that develops and provides medicines, vaccines, and consumer healthcare products. Its products include prescription and counterfeit medicines, and over-the-counter products. The company was founded in 1952 and is headquartered in Tadworth, the United Kingdom.

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.

New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.

Calchan Holdings Ltd. develops novel oral state-dependent calcium channel modulators for chronic pain. The company was founded on February 25, 2011 and is headquartered in London, the United Kingdom.

Calchan Ltd. operates as a biotechnology company, which develops novel oral state dependent calcium channel modulators for chronic pain. The company was founded by Brenda Elizabeth Reynolds in 2011 and is headquartered in London, the United Kingdom.

CuraSen Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapies to treat neurodegenerative diseases, including parkinson, alzheimer, and less common neurodegenerative disorders. The company was founded by Mehrdad Shamloo, Robert Booth, Anthony Ford, and Kathleen Sereda in 2018 and is headquartered in San Mateo, CA.

Rallybio LLC operates as a development-stage biotechnology company. The firm develops transformative therapies for patients. It focuses on bringing life-transforming medicines to patients with devastating and rare disorder. The company was founded by Martin Mackay, Stephen Uden and Jeffrey Fryer in 2018 and is headquartered in Farmington, CT.

Halda Therapeutics LLC engages in the development of research-stage drugs for novel therapeutic modality. The company is headquartered New Haven, CT.

Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA.

Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021.

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.

Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments.